Form 4: Anika Therapeutics Director Gary Fischetti Granted 14,164 Restricted Stock Units

Anika Therapeutics, Inc. Director Gary P. Fischetti was granted 14,164 restricted stock units (RSUs) on June 20, 2025, which will vest by June 2026.

Summary

• Gary P. Fischetti, a Director of Anika Therapeutics, Inc. (ANIK), acquired 14,164 shares of common stock on June 20, 2025.
• These shares were granted as Restricted Stock Units (RSUs) with a transaction price of $0, indicating they are part of a compensation plan.
• Each RSU represents the contingent right to receive one share of the Company's common stock.
• Following this transaction, Mr. Fischetti beneficially owns 41,613 shares directly.
• The RSUs are scheduled to vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a Form 4 is primarily a disclosure document, the grant of RSUs to a director is a standard practice that aligns management interests with shareholders, which is generally viewed favorably. There are no negative implications or significant risks disclosed.

Positives

• The grant of Restricted Stock Units to a director aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• This is a standard practice for compensating non-employee directors, promoting long-term commitment and retention.

Future Outlook

The 14,164 Restricted Stock Units granted to Director Gary P. Fischetti are scheduled to vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026, indicating a future transfer of shares upon meeting these conditions.

Management Comments

• "/s/ Gary P. Fischetti" Signature of the reporting person, Gary P. Fischetti, confirming the accuracy of the filing.

Industry Context

The grant of restricted stock units to non-employee directors is a common practice across various industries, including the biotechnology and medical device sectors where Anika Therapeutics operates. This method of compensation is widely used to attract and retain qualified board members by aligning their financial interests with the long-term performance of the company, similar to practices seen in peer companies.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a standard practice in the U.S. public company landscape, particularly within the healthcare and biotechnology sectors. Companies like Stryker Corporation, Zimmer Biomet Holdings, Inc., and other medical technology firms frequently utilize equity-based compensation, including RSUs, for their non-employee directors to foster long-term alignment with shareholder interests.
• The vesting schedule, tied to either an annual meeting or a specific future date (June 2026), is typical for RSU grants to directors, ensuring continued service and commitment over a defined period. This structure is comparable to compensation plans observed at similar-sized companies in the medical device space, which aim to balance immediate compensation with long-term incentives.

Related Party Transactions

• The grant of 14,164 Restricted Stock Units to Gary P. Fischetti, a Director of Anika Therapeutics, Inc., constitutes a transaction between the company and a related party (a director). This is a standard form of director compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value. However, it also represents a minor dilutive effect upon vesting.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The 14,164 Restricted Stock Units will vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026, at which point the underlying common stock will be issued to Mr. Fischetti.

Key Dates

Keywords

Anika Therapeutics, ANIK, SEC Form 4, Restricted Stock Units, RSUs, Director Compensation, Stock Grant, Beneficial Ownership, Corporate Governance